Developer of mRNA-based pathway activity profiling technology designed to revolutionize precision medicine by obtaining more insight into the mechanisms of disease. The company offers to utilize its extensive database with pathway activity profiles to support diagnostics and drug development, providing researchers with qPCR tests for decentralized use via a service testing facility in The Netherlands.
Allyx Therapeutics, founded in 2018 and located in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company specializes in a therapeutic drug that is an orally bioavailable small molecule, functioning as a silent allosteric modulator of mGluR5. This innovative approach aims to reverse neurodegeneration and preserve cognitive function in patients, offering a potential breakthrough in Alzheimer's treatment.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company based in Cambridge, Massachusetts, focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer’s disease. Incorporated in 2014, the company is advancing its lead product, AST-004, a novel small molecule designed for acute administration. This therapy aims to protect and repair damaged neurons by selectively stimulating astrocytes, a type of brain cell crucial for neuronal health. Astrocyte Pharmaceuticals is dedicated to demonstrating the neuroprotective benefits of its approach and improving outcomes for patients suffering from brain injuries.
Strategikon Pharma, Inc. is a technology firm that specializes in the design and development of software solutions aimed at optimizing the outsourcing processes in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a cloud-based platform that facilitates end-to-end management of clinical business operations, including planning, outsourcing, and financial management of clinical trials. This software creates a collaborative virtual environment that enhances communication and data integration between pharmaceutical companies and their service providers, moving away from traditional, labor-intensive methods such as Excel. By providing tools for clinical financial management, vendor performance metrics, and contract lifecycle management, Clinical Maestro enables biopharmaceutical firms to streamline their operations and reduce costs significantly. Founded in 2016 and headquartered in San Rafael, California, Strategikon also offers consulting services to support the establishment of clinical business operations for new entrants in the field.
Developer of medical imaging technology designed to improve early detection and diagnosis of diseases. The company offers specialized image capture systems and analysis tools, and provides high-resolution, three-dimensional, or multidimensional views of tissues or cells, potentially allowing medical professionals to identify abnormalities more easily and with greater accuracy, enabling users earlier intervention, improved treatment outcomes for patients, and potentially reduce overall healthcare costs.
Avisi Technologies Inc. is focused on developing innovative solutions to combat glaucoma, a leading cause of irreversible blindness. The company has created VisiPlate, a next-generation aqueous shunt designed for mid to late-stage glaucoma treatment. This product is notable for its ultrathin design, being 20 times thinner than a human hair, which facilitates a less invasive insertion procedure that reduces operating time and simplifies follow-up care. VisiPlate is constructed from alumina, a material recognized for its use in hip replacements, thus ensuring biocompatibility. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Avisi Technologies aims to address the challenges associated with current glaucoma treatments, including patient non-compliance and post-operative complications, ultimately striving to prevent blindness in affected individuals.
Watershed Therapeutics develops a novel, targeted drug-delivery platform for bladder diseases. The initial aim is to stop recurring urinary tract infections. The therapy can be tailored to help patients with overactive bladder, painful bladder syndrome, and bladder cancer.
Saccharo is a biotech start-up focused on immuno-oncology, dedicated to developing innovative therapeutic products for cancer treatment and other novel diseases. The company has discovered a unique polysaccharide that encases human cancer cells, which facilitates a mechanism of action for its therapies. This approach allows for multiple tumor-killing effects while maintaining a predicted safety profile and a broad therapeutic window, making it applicable to a variety of cancers. Saccharo aims to provide healthcare providers with effective treatment options that have the potential to cure patients.
Allyx Therapeutics, founded in 2018 and located in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company specializes in a therapeutic drug that is an orally bioavailable small molecule, functioning as a silent allosteric modulator of mGluR5. This innovative approach aims to reverse neurodegeneration and preserve cognitive function in patients, offering a potential breakthrough in Alzheimer's treatment.
Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, which uniquely integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology facilitates the identification and characterization of rare cells that are vital to understanding biological pathways and diseases. Celldom's initial applications focus on oncology, immunology, and stem cell biology, providing researchers with advanced tools to explore cellular heterogeneity and improve scientific outcomes.
Strategikon Pharma, Inc. is a technology firm that specializes in the design and development of software solutions aimed at optimizing the outsourcing processes in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a cloud-based platform that facilitates end-to-end management of clinical business operations, including planning, outsourcing, and financial management of clinical trials. This software creates a collaborative virtual environment that enhances communication and data integration between pharmaceutical companies and their service providers, moving away from traditional, labor-intensive methods such as Excel. By providing tools for clinical financial management, vendor performance metrics, and contract lifecycle management, Clinical Maestro enables biopharmaceutical firms to streamline their operations and reduce costs significantly. Founded in 2016 and headquartered in San Rafael, California, Strategikon also offers consulting services to support the establishment of clinical business operations for new entrants in the field.
Anubis Bio Corporation is an animal health company based in Orlando, Florida, focused on developing and manufacturing medical nutrition products designed to control diarrhea in dogs and cats. Founded in 2018, the company’s flagship product, DoggyStat, utilizes passive immunity to deliver fast-acting immune factors directly to the gastrointestinal tract. This innovative approach provides symptomatic relief and addresses infections that cause diarrhea in pets. Anubis Bio is committed to enhancing pet health through natural food products that support digestive health and promote normal intestinal function.
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.
Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, founded in 2012. The company specializes in developing medical products and research tools focused on male fertility management. Its notable offerings include the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a remote blood sampling device for diagnostic testing. Sandstone also manufactures the Trak fertility system, which consists of an engine, a disposable test plate, a sample collection cup, and a dropper, allowing men to monitor their sperm quality and enhance their fertility potential. Additionally, the company provides a mobile application that allows users to track fertility statistics over time, identify potential fertility issues, and take proactive steps to improve their reproductive health. Through these innovations, Sandstone Diagnostics aims to empower individuals to manage their fertility from the comfort of their own homes.
BioTrace Medical is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. BioTrace Medical is a stealth-stage company focused on the production of medical devices.
The company was founded by Aravind Swaminathan and Ellis Garai in 2013 and is based in San Mateo, California.
iDentical, Inc. develops personalized dental implants designed to enhance tooth replacement accessibility and affordability. Founded in 2018 and headquartered in California, the company specializes in drill-free, non-invasive implants that are tailored to the individual needs of patients. Utilizing advanced three-dimensional scanning and design technology, iDentical creates implants that allow family dentists to provide safer and more efficient treatments for those experiencing tooth loss. By focusing on personalized care, iDentical aims to revolutionize the dental implant industry, making high-quality tooth replacement options available to a broader audience.
Stimwave LLC is a medical device company focused on developing, manufacturing, and marketing wireless microsize injectable devices for neurology applications. The company's product offerings include the Freedom SCS System, a spinal cord stimulator designed to alleviate chronic low back and leg pain, and the StimQ PNS System, a peripheral nerve stimulator that addresses chronic pain by targeting specific peripheral nerves. Originally incorporated as Neural Micro Incorporated in 2010, Stimwave LLC is headquartered in Pompano Beach, Florida.
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.
Eumentis Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodevelopmental and neurodegenerative diseases. Based in Newton, Massachusetts, the company focuses on synthesizing established therapeutic knowledge with contemporary insights into brain function. Its primary product, EM-036, is a nitroaminoadamantane NMDA receptor antagonist aimed at treating Alzheimer's disease and autism-spectrum disorders. In addition to its drug development efforts, Eumentis Therapeutics also offers pre-clinical study, development, and testing services, contributing to advancements in neuropharmaceutical treatments. Established in 2019, the company strives to enhance healthcare solutions in the field of neurology.
Inhalon Biopharma, Inc. is focused on developing monoclonal antibodies that utilize innovative technology to trap pathogens in mucus secretions, specifically targeting respiratory infections. Founded in 2018 and based in Carrboro, North Carolina, the company aims to provide treatments and preventative solutions for respiratory syncytial virus (RSV), a significant cause of lung and respiratory tract infections in children. Inhalon Biopharma's inhaled immunotherapy platform is designed to harness the power of biologics for mucosal applications, enabling healthcare providers to effectively address acute respiratory infections.
S2 Genomics, Inc. is a company that specializes in developing integrated sample preparation systems designed to convert tissues and liquid samples into genomic samples suitable for analysis. Founded in 2016 and headquartered in Livermore, California, the company offers advanced spatial sequencing technology that captures the three-dimensional coordinates of individual cells within tissue, facilitating next-generation sequencing (NGS) readout. S2 Genomics aims to enhance genomic research by providing innovative solutions for the processing of raw biological samples.
S2 Genomics, Inc. is a company that specializes in developing integrated sample preparation systems designed to convert tissues and liquid samples into genomic samples suitable for analysis. Founded in 2016 and headquartered in Livermore, California, the company offers advanced spatial sequencing technology that captures the three-dimensional coordinates of individual cells within tissue, facilitating next-generation sequencing (NGS) readout. S2 Genomics aims to enhance genomic research by providing innovative solutions for the processing of raw biological samples.
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w
Chameleon Biosciences Inc. specializes in developing gene therapy solutions using Adeno Associated Virus (AAV) technology to address rare genetic diseases. Founded in 2017 and based in San Anselmo, California, the company focuses on delivering therapeutic proteins to targeted tissues while minimizing immune responses to enhance gene delivery and reduce immunogenicity. Chameleon aims to transform the treatment landscape for genetic disorders, particularly in infants, where a significant percentage of fatalities are attributed to these conditions. The company is dedicated to ensuring that affected children receive accurate, lower-dose treatments that can be administered multiple times as needed. By masking foreign proteins and shielding the viral capsid from antibodies, Chameleon seeks to increase the range of diseases that can be treated effectively, thereby improving patient outcomes and quality of life.
TeVido BioDevices, Inc. is a biotechnology start-up based in Austin, Texas, focused on developing tissue-engineered products for reconstructive surgery. Established in 2016, the company leverages 3D bio-printing technology and patients' living cells to create custom grafts tailored to individual needs. TeVido's innovative approach aims to enhance options for breast cancer survivors and others experiencing disfigurement, ultimately improving self-esteem and quality of life. In addition to its primary focus on breast reconstruction, TeVido's technology is applicable to a broad range of needs in wound healing and cosmetic surgery, addressing various unmet demands in these fields. The company's advancements in cellular therapy and manufacturing techniques enable the restoration of lost skin color, offering significant improvements in surgical outcomes.
First Light Biosciences develops breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare-Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with unprecedented affordability and ease-of-use.
TransformativeMed, Inc. specializes in developing software solutions for hospitals and health application partners, focusing on enhancing the integration of electronic medical records (EMR) with clinician workflows. Founded in 2007 and based in Seattle, the company offers a range of Smart Health Apps, which are designed to facilitate seamless communication and data management within healthcare settings. Notable solutions include CORES Smart Handoffs, enabling efficient patient sign-outs between providers; GlycemiCare Smart Glucose, aimed at improving glycemic control and patient safety; and ACR Select Smart Imaging, which provides decision support for imaging at the point of order entry. TransformativeMed has established itself as a leader in EMR integration, empowering over 40 hospitals to maximize their EMR investments while focusing on improving patient outcomes.
S2 Genomics, Inc. is a company that specializes in developing integrated sample preparation systems designed to convert tissues and liquid samples into genomic samples suitable for analysis. Founded in 2016 and headquartered in Livermore, California, the company offers advanced spatial sequencing technology that captures the three-dimensional coordinates of individual cells within tissue, facilitating next-generation sequencing (NGS) readout. S2 Genomics aims to enhance genomic research by providing innovative solutions for the processing of raw biological samples.
Purissima, Inc. is a biotherapeutics company founded in 2017 and headquartered in Sunnyvale, California. The company specializes in producing active pharmaceutical ingredient (API) grade molecules by leveraging a unique platform that utilizes the fermentation of heterotrophic microalgae. Through this innovative approach, Purissima aims to advance the development of biotherapeutics and contribute to the pharmaceutical industry.
Virion Therapeutics, LLC, a biotechnology company, develops immune-based treatments for virally-associated cancers and chronic viral infections. It offers ChiVax and ChiVax-gD vaccines to induce potent and sustained T cell-mediated immune responses against transformed and infected cells. Virion Therapeutics, LLC was incorporated in 2018 and is based in Newark, Delaware.
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.
TheraDep Technologies, Inc. is a manufacturer of biologic materials based in Palo Alto, California, founded in 2015. The company specializes in developing innovative surface coatings that are biocompatible, drug-eluting, growth-promoting, and therapeutic. Its flagship product, TheraDep, addresses various medical conditions and enhances the functionality of medical devices. Additionally, TheraDep offers TherGen, which combines the therapeutic effects of Cold Atmospheric Plasma with collagen application, and BioDep, which provides coatings for medical devices that facilitate the deposition of biologic materials and drugs. The company also produces BioDep Labware, which employs a single-step dry process to apply biologic materials for use in diagnostics and laboratory equipment. TheraDep Technologies aims to provide tailored alternatives for medical device and labware companies, improving patient treatment and device performance.
Seal Rock Therapeutics, Inc. specializes in the discovery and development of small molecule inhibitors targeting ASK1 (apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company is primarily focused on addressing hepatic conditions, particularly non-alcoholic steatohepatitis (NASH), which is associated with fatty liver disease and characterized by liver inflammation and damage leading to fibrosis. Seal Rock aims to provide effective treatments for NASH and other inflammatory and fibrotic disorders that currently lack approved therapies. In addition to hepatic indications, the potential applications of ASK1 inhibitors extend to cardiac, immunological, and neurodegenerative conditions.
Ark.one Health develops a predictive analytics platform for health care systems and plans. The company provides financial performance improvement analytics to health systems as a service.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.
Seal Rock Therapeutics, Inc. specializes in the discovery and development of small molecule inhibitors targeting ASK1 (apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company is primarily focused on addressing hepatic conditions, particularly non-alcoholic steatohepatitis (NASH), which is associated with fatty liver disease and characterized by liver inflammation and damage leading to fibrosis. Seal Rock aims to provide effective treatments for NASH and other inflammatory and fibrotic disorders that currently lack approved therapies. In addition to hepatic indications, the potential applications of ASK1 inhibitors extend to cardiac, immunological, and neurodegenerative conditions.
Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Embolx, Inc. is a medical device manufacturer based in Sunnyvale, California, focused on creating catheter-based systems for cancer treatment. Founded in 2013, the company has developed innovative devices such as the Sniper, a drug delivery balloon microcatheter that enhances the precision of delivering therapeutic agents directly to tumors while minimizing the risk of affecting surrounding healthy tissues. Utilizing a technique known as Low Pressure Embolization (LPE), Embolx's devices regulate pressure to improve drug distribution within the tumor and eliminate non-target delivery. This technology aims to set a new standard in minimally invasive localized cancer therapy, while also addressing conditions such as benign prostatic hyperplasia and uterine fibroids.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Thrive Bioscience, Inc. is a life science company based in Beverly, Massachusetts, focused on enhancing cell culture practices through innovative technology. Established in 2014, the company specializes in automated non-microbial cell culture instruments and software that facilitate research, drug discovery, drug development, and regenerative medicine. Its flagship product, CellAssist, allows cell culture researchers to efficiently image, analyze, and document various cells and workflows within a centralized database. By integrating microscopy, robotics, and fluidics, Thrive's instruments enable biologists to achieve consistent and reproducible results while providing comprehensive analysis, reports, and guidance on cell culture processes.
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.
Retrotope Inc. is a biotechnology company that focuses on developing drugs for the treatment of degenerative and intractable diseases, particularly neurological disorders. Based in Los Altos, California, the company aims to preserve and restore mitochondrial health through a novel drug platform that targets metabolic processes linked to oxidative stress. Retrotope's portfolio includes RT001, a drug designed for infantile neuroaxonal dystrophy, and it actively works on treatments for conditions such as Parkinson's disease, Alzheimer's disease, mitochondrial myopathies, and retinopathies. Established in 2006, Retrotope employs innovative approaches, including the isotope effect, to slow damaging biological pathways, thereby addressing various major classes of biopolymers and advancing its commitment to improving patient outcomes in degenerative diseases.
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.
Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.
Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.
Gemmus Pharma Inc. is a biotechnology company based in San Francisco, California, founded in 2007. The company focuses on developing therapeutics for the treatment of influenza and other infectious diseases. Its lead candidates include GP1001, a non-peptidic eicosanoid analog designed for serious influenza infections that may require hospitalization, and GP1681, which aims to alleviate influenza symptoms by reducing the exaggerated cytokine response induced by the virus. GP1001 can be used as a stand-alone treatment or in combination with antiviral drugs such as oseltamivir. Gemmus Pharma has received support from the National Institute of Allergy and Infectious Disease and has plans to file an investigational new drug application with the FDA to advance its influenza treatment initiatives.
Physcient, Inc. is a company based in Durham, North Carolina, that specializes in the manufacture of surgical instruments, particularly the Differential Dissector designed for blunt dissection. Founded in 2007 by three experienced scientists and executives, Physcient focuses on enhancing surgical technology to improve patient recovery times without altering existing surgical procedures. The Differential Dissector is utilized in various surgical fields, including plastic surgery, thoracic, gastrointestinal, gynecological, urological, peripheral vascular, and orthopedic surgeries. This innovative instrument enables surgeons to separate critical tissues, such as blood vessels and nerves, from surrounding tissues by taking advantage of their differing biomechanical properties, allowing for precise differential dissection and improved surgical outcomes.
Carmenta Bioscience is a privately held medical technology company dedicated to improving maternal and fetal health. Spun-out of Stanford University School of Medicine in 2012, Carmenta Bioscience is currently developing a highly accurate, serum-based diagnostic test for preeclampsia.
NuMedii, Inc. is a biotechnology company focused on discovering and developing drug candidates by leveraging life sciences big data technology. Founded in 2008 and headquartered in San Mateo, California, NuMedii utilizes an extensive array of biological, pharmacological, and clinical data to identify new therapeutic options and indications for existing drugs. The company aims to de-risk drug candidates by analyzing complex biological networks related to diseases, thereby addressing unmet medical needs. NuMedii collaborates with pharmaceutical companies for the clinical development and commercialization of its drug candidates, supported by strategic alliances with partners such as Aptalis Pharma and Three Lakes Partners, LLC.
NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.
nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.
Gemmus Pharma Inc. is a biotechnology company based in San Francisco, California, founded in 2007. The company focuses on developing therapeutics for the treatment of influenza and other infectious diseases. Its lead candidates include GP1001, a non-peptidic eicosanoid analog designed for serious influenza infections that may require hospitalization, and GP1681, which aims to alleviate influenza symptoms by reducing the exaggerated cytokine response induced by the virus. GP1001 can be used as a stand-alone treatment or in combination with antiviral drugs such as oseltamivir. Gemmus Pharma has received support from the National Institute of Allergy and Infectious Disease and has plans to file an investigational new drug application with the FDA to advance its influenza treatment initiatives.
Niveus Medical, Inc. develops and provides muscle stimulation systems designed to maintain and improve the strength of key muscle groups, particularly the quadriceps, during periods of sedation and bed rest. Founded in 2008 and located in Redwood City, California, the company's technology, branded as IntelliSTIM, is indicated for enhancing range of motion in the knee joint, preventing disuse atrophy, re-educating muscles, relieving muscle spasms, and promoting local blood circulation. These systems facilitate quicker treatment initiation in intensive care settings, thereby increasing the likelihood of successful recovery outcomes for patients.
MoMelan Technologies, Inc. operates as a developer of a device to treat skin disorders by expanding the surface area of skin grafts. The company was incorporated in 2009 and is based in Cambridge, Massachusetts. MoMelan Technologies, Inc. operates as a subsidiary of Acelity L.P. Inc.
OncoHealth is a company that specializes in creating screening devices aimed at the detection and diagnosis of cancer. The primary focus of its devices is the development of protein bio-markers, which are essential for the screening and diagnostic processes related to cervical cancer and other cancers associated with human papillomavirus (HPV). By advancing these technologies, OncoHealth enables medical professionals to effectively monitor, diagnose, and treat cancer, thereby contributing to improved patient outcomes in oncology.
OncoHealth is a company that specializes in creating screening devices aimed at the detection and diagnosis of cancer. The primary focus of its devices is the development of protein bio-markers, which are essential for the screening and diagnostic processes related to cervical cancer and other cancers associated with human papillomavirus (HPV). By advancing these technologies, OncoHealth enables medical professionals to effectively monitor, diagnose, and treat cancer, thereby contributing to improved patient outcomes in oncology.
Allylix, Inc. is an early-stage biotechnology company based in San Diego, California, with research and development laboratories in Lexington, Kentucky. Founded in 2002, the company specializes in developing terpene products and their derivatives for various markets, including flavor and fragrance, food ingredients, pharmaceuticals, agriculture, and biofuels. Notable among its offerings is nootkatone, a grapefruit flavor used in beverages such as fruit juices and citrus-flavored sodas. Additionally, Allylix works on sesquiterpenes that contribute to the aroma chemical segment of the flavor and fragrance industry, as well as production platforms for the pharmaceutical and nutraceutical sectors.
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary oral vaccine platform. The company’s product pipeline features a norovirus vaccine, which has completed Phase I clinical trials, and an oral tablet vaccine targeting the GI.1 and GII.4 norovirus strains. Additionally, Vaxart is advancing a seasonal influenza vaccine currently in Phase II trials for H1 influenza, as well as vaccines for respiratory syncytial virus and coronavirus. The company is also engaged in developing therapeutic immune-oncology vaccines aimed at cervical cancer and dysplasia linked to human papillomavirus. Furthermore, Vaxart has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform in the context of a universal influenza vaccine program. Founded in 2004, Vaxart is dedicated to creating innovative vaccine solutions to combat infectious diseases.
Velomedix, Inc. is a therapeutic hypothermia company based in Menlo Park, California. The company specializes in technologies designed to protect the body’s organs during ischemic or inflammatory insults. Velomedix's innovative approach aims to provide an effective solution for preserving organ function in critical medical situations.
Verdezyne is a company focused on synthetic biology, utilizing its expertise to develop innovative solutions for producing chemicals from renewable sources. By leveraging advanced computational algorithms and proprietary gene libraries, Verdezyne engineers proteins and metabolic pathways to optimize fermentation processes. This approach allows the company to create sustainable alternatives to petrochemicals, significantly reducing reliance on oil. Its platform integrates proven manufacturing technologies to generate a diverse range of chemical building blocks and additives that are applicable in various everyday products. Through its efforts, Verdezyne aims to provide cost-effective and environmentally friendly chemical solutions.
Breathe Technologies, Inc. develops and manufactures innovative medical technologies aimed at treating respiratory insufficiency diseases. Founded in 2005 and based in Irvine, California, the company specializes in non-invasive open ventilation systems designed for patients suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Its lightweight mechanical ventilators are equipped with features that support continuous ventilation while promoting patient mobility, making them suitable for use in various healthcare settings, including intensive care units and pulmonary rehabilitation. Breathe Technologies operates as a subsidiary of Hill-Rom, Inc., focusing on enhancing respiratory care both in hospital environments and at home.
Satoris is a company focused on the development and commercialization of neurodiagnostic tests aimed at identifying neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is dedicated to creating tests that provide early, accurate, and clinically relevant diagnoses, which can lead to improved patient care and reduced healthcare costs. By prioritizing convenience and affordability, Satoris aims to enhance access to essential diagnostic services for patients facing these neurological conditions.
Allylix, Inc. is an early-stage biotechnology company based in San Diego, California, with research and development laboratories in Lexington, Kentucky. Founded in 2002, the company specializes in developing terpene products and their derivatives for various markets, including flavor and fragrance, food ingredients, pharmaceuticals, agriculture, and biofuels. Notable among its offerings is nootkatone, a grapefruit flavor used in beverages such as fruit juices and citrus-flavored sodas. Additionally, Allylix works on sesquiterpenes that contribute to the aroma chemical segment of the flavor and fragrance industry, as well as production platforms for the pharmaceutical and nutraceutical sectors.
Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary oral vaccine platform. The company’s product pipeline features a norovirus vaccine, which has completed Phase I clinical trials, and an oral tablet vaccine targeting the GI.1 and GII.4 norovirus strains. Additionally, Vaxart is advancing a seasonal influenza vaccine currently in Phase II trials for H1 influenza, as well as vaccines for respiratory syncytial virus and coronavirus. The company is also engaged in developing therapeutic immune-oncology vaccines aimed at cervical cancer and dysplasia linked to human papillomavirus. Furthermore, Vaxart has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform in the context of a universal influenza vaccine program. Founded in 2004, Vaxart is dedicated to creating innovative vaccine solutions to combat infectious diseases.
Fluxion Biosciences, Inc. develops analytical instruments for functional cellular analysis aimed at life sciences, drug discovery, and diagnostic applications. Founded in 2005 and based in Alameda, California, the company specializes in a proprietary microfluidic platform that allows for precise cellular manipulation and rapid compound addition. Its primary offerings include the IsoFlux Liquid Biopsy System, designed for enriching rare cell populations such as circulating tumor cells, as well as various cell enrichment and downstream analysis kits. Additionally, Fluxion provides BioFlux systems for live cell analysis under shear flow and IonFlux systems for automated patch clamping. The company serves a diverse clientele, including biotechnology and pharmaceutical firms, academic institutions, and government research organizations, and offers its products through a network of distributors both domestically and internationally.
Verdezyne is a company focused on synthetic biology, utilizing its expertise to develop innovative solutions for producing chemicals from renewable sources. By leveraging advanced computational algorithms and proprietary gene libraries, Verdezyne engineers proteins and metabolic pathways to optimize fermentation processes. This approach allows the company to create sustainable alternatives to petrochemicals, significantly reducing reliance on oil. Its platform integrates proven manufacturing technologies to generate a diverse range of chemical building blocks and additives that are applicable in various everyday products. Through its efforts, Verdezyne aims to provide cost-effective and environmentally friendly chemical solutions.
VasoNova, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing and marketing innovative vascular navigation systems. The company is known for its self-guided PICC catheter and the VasoNova Vascular Positioning System, which utilizes an algorithm-based approach to assist healthcare providers and clinicians in the optimal placement of vascular access devices. Through its advanced technologies, VasoNova aims to improve patient outcomes and streamline vascular access procedures.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
Verdezyne is a company focused on synthetic biology, utilizing its expertise to develop innovative solutions for producing chemicals from renewable sources. By leveraging advanced computational algorithms and proprietary gene libraries, Verdezyne engineers proteins and metabolic pathways to optimize fermentation processes. This approach allows the company to create sustainable alternatives to petrochemicals, significantly reducing reliance on oil. Its platform integrates proven manufacturing technologies to generate a diverse range of chemical building blocks and additives that are applicable in various everyday products. Through its efforts, Verdezyne aims to provide cost-effective and environmentally friendly chemical solutions.
NSpine, Inc. engages in designing and developing devices for stabilization and motion preservation of the lumbar spine via minimally invasive surgery. Its product includes NFlex, a titanium pedicle screw system, which provides support to the spinal motion segment and also used in non-fusion/hybrid applications.
Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.